Sage Therapeutics, Inc. financial data

Symbol
SAGE on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.06K % -2.94%
Debt-to-equity 10.6 % +4.96%
Return On Equity -50.3 % +19.8%
Return On Assets -45.5 % +20.1%
Operating Margin -350 % +94.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.2M shares +2.01%
Common Stock, Shares, Outstanding 61.2M shares +2.01%
Entity Public Float 2.47B USD +46.6%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 61.1M shares +2.01%
Weighted Average Number of Shares Outstanding, Diluted 61.1M shares +2.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 106M USD +838%
Research and Development Expense 253M USD -33.6%
Operating Income (Loss) -372M USD +46.2%
Net Income (Loss) Attributable to Parent -338M USD +48.5%
Earnings Per Share, Basic -5.57 USD/shares +49.3%
Earnings Per Share, Diluted -5.57 USD/shares +49.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.6M USD -33%
Marketable Securities, Current 470M USD -35.4%
Accounts Receivable, after Allowance for Credit Loss, Current 14.9M USD -33.9%
Assets, Current 605M USD -35.2%
Property, Plant and Equipment, Net 1.02M USD -58.3%
Operating Lease, Right-of-Use Asset 11.3M USD +86.7%
Other Assets, Noncurrent 5.18M USD -21.5%
Assets 622M USD -34.5%
Accounts Payable, Current 7.13M USD -36%
Employee-related Liabilities, Current 17M USD +20.5%
Accrued Liabilities, Current 53.2M USD -53.7%
Liabilities, Current 60.4M USD -54.6%
Operating Lease, Liability, Noncurrent 10.2M USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 70.6M USD -46.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 901K USD
Retained Earnings (Accumulated Deficit) -2.87B USD -13.3%
Stockholders' Equity Attributable to Parent 552M USD -32.4%
Liabilities and Equity 622M USD -34.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD +75.4%
Net Cash Provided by (Used in) Financing Activities 1.56M USD -41.7%
Net Cash Provided by (Used in) Investing Activities 139M USD -28.4%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 61.2M shares +2.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 103M USD +135%
Deferred Tax Assets, Valuation Allowance 735M USD +23.9%
Deferred Tax Assets, Gross 735M USD +23.9%
Operating Lease, Liability 10.3M USD
Depreciation 336K USD +4.03%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -333M USD +48.4%
Lessee, Operating Lease, Liability, to be Paid 14.1M USD
Property, Plant and Equipment, Gross 9.41M USD +4.63%
Operating Lease, Liability, Current 83K USD -98.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.46M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.85M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.06M USD
Deferred Tax Assets, Operating Loss Carryforwards 429M USD +23.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 7.74M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.14M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 58M USD -23.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%